Journal: Blood research
This publication reviews the evolving treatment landscape for transplant-ineligible multiple myeloma (MM) patients.
It highlights the shift from melphalan-based regimens to combinations incorporating proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. These combinations result in doublet, triplet, and quadruple therapies that:
- Improve survival
- Achieve deeper responses, such as minimal residual disease negativity
- Maintain tolerability
The review also emphasizes the increasing importance of frailty assessment tools to tailor treatment for older, frail patients. Additionally, it discusses emerging strategies aimed at further improving outcomes in this population.